a Phase II Study in Primary Central Nervous System Lymphoma
High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma - a Phase II Study
Sponsor: Chi Mei Medical Hospital
This PHASE2 trial investigates Primary Central Nervous System Lymphoma and is currently ongoing. Chi Mei Medical Hospital leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
▶ Show 3 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Sep 2020 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chi Mei Medical Hospital
- China Medical University Hospital
- Mackay Memorial Hospital
- National Cheng-Kung University Hospital
- National Health Research Institutes, Taiwan
- National Taiwan University Hospital
- Taichung Veterans General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .